+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Biopharmaceuticals Market - Global Forecast to 2030- Product Image
Biopharmaceuticals Market - Global Forecast to 2030- Product Image
Sale

Biopharmaceuticals Market - Global Forecast to 2030

  • PDF Icon

    Report

  • 180 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 5665849
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Biopharmaceuticals Market grew from USD 627.19 billion in 2024 to USD 690.04 billion in 2025. It is expected to continue growing at a CAGR of 9.84%, reaching USD 1.10 trillion by 2030.

The biopharmaceutical sector has emerged as a critical driver of next-generation healthcare solutions, combining cutting-edge science with robust manufacturing capabilities to address unmet patient needs. Advances in molecular biology, high-throughput screening, and precision medicine have accelerated the development of therapies targeting complex diseases, transforming once-intractable conditions into manageable or curable ones. As regulatory frameworks evolve to accommodate innovative modalities-from mRNA vaccines to gene and cell therapies-stakeholders across research, manufacturing, and distribution must adapt to shifting expectations and operational paradigms. This introduction sets the stage for an in-depth exploration of the forces reshaping the landscape, including emerging therapies, tariff implications, market segmentation, regional dynamics, and key players. Decision-makers will gain a holistic view of current trends and actionable insights, empowering strategic planning and investment decisions in a sector defined by rapid innovation and stringent regulatory oversight.

Transformative Shifts Redefining Biopharma Development

Rapid technological breakthroughs and shifting patient needs are redefining the biopharmaceutical paradigm. The advent of messenger RNA platforms has propelled vaccine development into new territory, while gene editing tools like CRISPR are moving from concept to clinic. Simultaneously, digital health solutions-wearables, remote monitoring, AI-driven diagnostics-are enhancing patient engagement and enabling real-time insights into treatment efficacy. These transformative shifts are supported by an ecosystem increasingly focused on personalized medicine, where immunotherapies tailored to individual genetic profiles are setting new standards for efficacy and safety.

Moreover, the rise of biosimilars is introducing competitive pricing pressures that encourage original innovators to optimize production efficiency and invest in next-generation biologics. Partnerships between established pharmaceutical companies and biotech startups are proliferating, fostering collaborative R&D models that accelerate go-to-market timelines. Regulatory bodies are responding with adaptive approval pathways and accelerated review processes, recognizing the urgency of addressing global health challenges. Together, these dynamics are charting a course toward a more agile, patient-centric industry, ready to tackle the complex therapeutic needs of tomorrow.

Assessing the Cumulative Impact of U.S. Tariffs in 2025 on Biopharma

In 2025, the imposition of new U.S. tariffs on imported biopharmaceutical raw materials and advanced manufacturing equipment is generating significant ripple effects across global supply chains. Increased duties on chromatography resins, single-use bioreactor bags, and critical reagents are inflating input costs for domestic producers and contract development and manufacturing organizations (CDMOs). In response, companies are reassessing sourcing strategies, exploring near-shoring options, and negotiating volume commitments to mitigate cost escalations.

These tariff measures are also driving strategic reevaluation of manufacturing footprints. Firms that previously relied on offshore capacity in Europe or Asia to optimize costs are now exploring onshore expansions to shield production from trade volatility. While this transition entails capital investment in new or retrofitted facilities, it ultimately bolsters supply chain resilience and reduces lead-time risks. Downstream, payers and healthcare providers are bracing for pricing adjustments, prompting stakeholders to engage in proactive dialogue on value-based contracting and risk-sharing models. By anticipating these tariff-induced shifts, biopharmaceutical leaders can develop robust contingency plans that safeguard both profitability and patient access.

Key Segmentation Insights Unlocking Market Dynamics

A nuanced understanding of market segments illuminates opportunities for targeted innovation and resource allocation. When viewed through the lens of drug type, the industry encompasses biologics-examined across monoclonal antibodies, therapeutic proteins, and vaccines-alongside biosimilars, which include insulin biosimilars and monoclonal antibody analogs, as well as small molecule drugs subdivided into branded and generic offerings. Each category follows distinct regulatory pathways and cost structures, compelling developers to tailor strategies around formulation complexity, patent landscapes, and manufacturing scalability.

Considering therapeutic application further refines investment priorities. Cardiology programs address coronary artery disease and hypertension through advanced protein therapeutics and peptide analogs. Infectious disease initiatives span COVID-19 vaccine boosters, HIV/AIDS antiretroviral regimens, and next-generation influenza vaccines. Oncology pipelines concentrate on breast cancer, colorectal cancer, and lung cancer, leveraging targeted antibodies, antibody-drug conjugates, and immuno-oncology combinations to enhance patient outcomes.

Finally, development phase segmentation highlights risk management and capital deployment needs. Clinical trials progress through Phase I, II, and III studies, each stage demanding escalating investment in patient recruitment, data monitoring, and regulatory engagement. Preclinical efforts, including continuous preclinical trials, inform candidate selection and safety profiling. Companies navigating the regulatory approval phase must align dossier preparation, manufacturing validation, and post-approval commitments to secure market authorization.

Regional Insights Highlighting Growth and Challenges

Regional performance varies widely, shaped by regulatory environments, patient demographics, and infrastructure maturity. In the Americas, the United States leads with a robust biomanufacturing base, extensive clinical trial networks, and a reimbursement framework that rewards innovation, while Latin American markets are gradually expanding access through public-private partnerships and localized production agreements. Europe, the Middle East & Africa present heterogeneous landscapes: Western Europe’s well-established regulatory harmonization under the EMA supports rapid adoption of novel therapies; the Middle East prioritizes centralized procurement strategies to secure vaccine and biologic supplies; and Africa faces challenges in cold-chain logistics despite growing demand for biosimilars.

Asia-Pacific stands out as a high-growth corridor, driven by China’s strategic focus on self-sufficiency in biologics, India’s thriving generic and biosimilar manufacturing, and Japan’s advanced cell-therapy pipeline supported by expedited review processes. Australia is enhancing regulatory frameworks to attract global clinical trials, while Southeast Asian nations are strengthening pharmacovigilance systems to support market entry. Across these regions, collaboration between multinational corporations and regional partners is key to navigating local regulations and unlocking patient access.

Leading Biopharmaceutical Companies Driving Innovation

Innovation is propelled by a diverse roster of industry leaders and niche specialists. Abbott Laboratories continues to pioneer diagnostic platforms that accelerate personalized therapy selection, while AbbVie Inc. focuses on immunology and oncology pipelines. Abgenex advances antibody fragment technologies, and Amgen Inc. leverages its biologics expertise to expand monoclonal antibody portfolios. AstraZeneca PLC integrates AI into target discovery, complemented by Avidea Technologies’ work on precision adjuvant systems. Bayer AG invests in protein engineering for next-generation vaccines.

Bio-Techne Corporation delivers reagents and assays essential for process development, as Biogen Inc. advances neurodegenerative disease programs. bioMérieux SA enhances diagnostic throughput for infectious diseases, and Bristol-Myers Squibb Company drives immuno-oncology collaborations. BTL Biotechno Labs Pvt. Ltd. emerges in Asia as a contract research innovator, while Eli Lilly and Company scales up antibody-drug conjugate production. F. Hoffmann-La Roche AG refines personalized oncology regimens, and Ferring Pharmaceuticals expands peptide therapeutics in reproductive health.

GlaxoSmithKline PLC and Ipsen Pharma co-develop vaccine platforms, supported by Johnson & Johnson Services, Inc.’s end-to-end manufacturing solutions. LG Chem Life Sciences Innovation Center, Inc. accelerates cell-therapy manufacturing, while Merck & Co., Inc. and Novartis AG drive mRNA and gene-editing initiatives, respectively. Nordic BioSite offers specialized antibody discovery services. Novo Nordisk A/S maintains leadership in insulin analogs, and Pfizer, Inc. partners on global vaccine distribution. Sanofi S.A. emphasizes next-generation recombinant biologics, Takeda Pharmaceutical Company Limited focuses on plasma-derived therapies, and Thermo Fisher Scientific Inc. underpins analysis and quality control across the value chain.

Actionable Recommendations for Industry Leadership

To maintain competitive advantage and deliver patient value, industry leaders should prioritize three strategic imperatives. First, strengthen supply chain resilience by diversifying raw material sources and evaluating onshore manufacturing expansions; proactive scenario planning and strategic partnerships with CDMOs can mitigate tariff and logistics risks. Second, accelerate digital transformation across R&D and commercial functions; deploying AI-powered analytics for biomarker identification and real-time manufacturing process monitoring enhances efficiency and drives down cycle times. Third, adopt value-based contracting models that align pricing with clinical outcomes; collaboration with payers to structure risk-sharing agreements can facilitate earlier patient access while safeguarding revenue streams.

In parallel, companies must cultivate agile regulatory strategies, leveraging accelerated pathways and adaptive trial designs to compress development timelines. Investment in modular, single-use facilities and continuous manufacturing technologies supports rapid scale-up of emerging modalities. Finally, forging cross-sector alliances-with academic institutions, technology startups, and non-profit organizations-can diversify innovation pipelines and address complex public health challenges. By executing this integrated playbook, organizations will be well-positioned to navigate market uncertainties and sustain long-term growth.

Conclusion: Navigating the Future of Biopharma

The biopharmaceutical landscape is poised for sustained transformation as science, technology, and policy converge to address pressing healthcare needs. Leaders who integrate robust risk-management practices, embrace digital and manufacturing innovation, and foster collaborative ecosystems will unlock new avenues for growth. As regional dynamics evolve, tailored strategies that reflect local regulatory, economic, and patient-access realities will be critical. Moreover, a relentless focus on patient-centric value, demonstrated through outcome-driven pricing and real-world evidence generation, will differentiate organizations in an increasingly competitive market. Looking ahead, the capacity to adapt swiftly and anticipate emerging trends-such as next-generation gene therapies, decentralized clinical trials, and novel financing models-will define the industry’s next chapter.

Market Segmentation & Coverage

This research report categorizes the Biopharmaceuticals Market to forecast the revenues and analyze trends in each of the following sub-segmentations:

  • Biologics
    • Monoclonal Antibodies
    • Therapeutic Proteins
    • Vaccines
  • Biosimilars
    • Insulin Biosimilars
    • Monoclonal Antibodies Biosimilars
  • Small Molecule Drugs
    • Branded Drugs
    • Generic Drugs
  • Cardiology
    • Coronary Artery Disease
    • Hypertension
  • Infectious Diseases
    • COVID-19
    • HIV/AIDS
    • Influenza
  • Oncology
    • Breast Cancer
    • Colorectal Cancer
    • Lung Cancer
  • Clinical Trials
    • Phase I
    • Phase II
    • Phase III
  • Preclinical
    • Continuous Preclinical Trials
  • Regulatory Approval

This research report categorizes the Biopharmaceuticals Market to forecast the revenues and analyze trends in each of the following sub-regions:

  • Americas
    • Argentina
    • Brazil
    • Canada
    • Mexico
    • United States
      • California
      • Florida
      • Illinois
      • New York
      • Ohio
      • Pennsylvania
      • Texas
  • Asia-Pacific
    • Australia
    • China
    • India
    • Indonesia
    • Japan
    • Malaysia
    • Philippines
    • Singapore
    • South Korea
    • Taiwan
    • Thailand
    • Vietnam
  • Europe, Middle East & Africa
    • Denmark
    • Egypt
    • Finland
    • France
    • Germany
    • Israel
    • Italy
    • Netherlands
    • Nigeria
    • Norway
    • Poland
    • Qatar
    • Russia
    • Saudi Arabia
    • South Africa
    • Spain
    • Sweden
    • Switzerland
    • Turkey
    • United Arab Emirates
    • United Kingdom

This research report categorizes the Biopharmaceuticals Market to delves into recent significant developments and analyze trends in each of the following companies:

  • Abbott Laboratories
  • AbbVie Inc.
  • Abgenex
  • Amgen Inc.
  • AstraZeneca PLC
  • Avidea Technologies
  • Bayer AG
  • Bio-Techne Corporation
  • Biogen Inc.
  • bioMérieux SA
  • Bristol-Myers Squibb Company
  • BTL Biotechno Labs Pvt. Ltd.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche AG
  • Ferring Pharmaceuticals
  • GlaxoSmithKline PLC
  • Ipsen Pharma
  • Johnson & Johnson Services, Inc.
  • LG Chem Life Sciences Innovation Center, Inc.
  • Merck & Co., Inc.
  • Nordic BioSite
  • Novartis AG
  • Novo Nordisk A/S
  • Pfizer, Inc.
  • Sanofi S.A.
  • Takeda Pharmaceutical Company Limited
  • Thermo Fisher Scientific Inc.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Biopharmaceuticals Market, by Drug Type
8.1. Introduction
8.2. Biologics
8.2.1. Monoclonal Antibodies
8.2.2. Therapeutic Proteins
8.2.3. Vaccines
8.3. Biosimilars
8.3.1. Insulin Biosimilars
8.3.2. Monoclonal Antibodies Biosimilars
8.4. Small Molecule Drugs
8.4.1. Branded Drugs
8.4.2. Generic Drugs
9. Biopharmaceuticals Market, by Therapeutic Application
9.1. Introduction
9.2. Cardiology
9.2.1. Coronary Artery Disease
9.2.2. Hypertension
9.3. Infectious Diseases
9.3.1. COVID-19
9.3.2. HIV/AIDS
9.3.3. Influenza
9.4. Oncology
9.4.1. Breast Cancer
9.4.2. Colorectal Cancer
9.4.3. Lung Cancer
10. Biopharmaceuticals Market, by Development Phase
10.1. Introduction
10.2. Clinical Trials
10.2.1. Phase I
10.2.2. Phase II
10.2.3. Phase III
10.3. Preclinical
10.3.1. Continuous Preclinical Trials
10.4. Regulatory Approval
11. Americas Biopharmaceuticals Market
11.1. Introduction
11.2. Argentina
11.3. Brazil
11.4. Canada
11.5. Mexico
11.6. United States
12. Asia-Pacific Biopharmaceuticals Market
12.1. Introduction
12.2. Australia
12.3. China
12.4. India
12.5. Indonesia
12.6. Japan
12.7. Malaysia
12.8. Philippines
12.9. Singapore
12.10. South Korea
12.11. Taiwan
12.12. Thailand
12.13. Vietnam
13. Europe, Middle East & Africa Biopharmaceuticals Market
13.1. Introduction
13.2. Denmark
13.3. Egypt
13.4. Finland
13.5. France
13.6. Germany
13.7. Israel
13.8. Italy
13.9. Netherlands
13.10. Nigeria
13.11. Norway
13.12. Poland
13.13. Qatar
13.14. Russia
13.15. Saudi Arabia
13.16. South Africa
13.17. Spain
13.18. Sweden
13.19. Switzerland
13.20. Turkey
13.21. United Arab Emirates
13.22. United Kingdom
14. Competitive Landscape
14.1. Market Share Analysis, 2024
14.2. FPNV Positioning Matrix, 2024
14.3. Competitive Analysis
14.3.1. Abbott Laboratories
14.3.2. AbbVie Inc.
14.3.3. Abgenex
14.3.4. Amgen Inc.
14.3.5. AstraZeneca PLC
14.3.6. Avidea Technologies
14.3.7. Bayer AG
14.3.8. Bio-Techne Corporation
14.3.9. Biogen Inc.
14.3.10. bioMérieux SA
14.3.11. Bristol-Myers Squibb Company
14.3.12. BTL Biotechno Labs Pvt. Ltd.
14.3.13. Eli Lilly and Company
14.3.14. F. Hoffmann-La Roche AG
14.3.15. Ferring Pharmaceuticals
14.3.16. GlaxoSmithKline PLC
14.3.17. Ipsen Pharma
14.3.18. Johnson & Johnson Services, Inc.
14.3.19. LG Chem Life Sciences Innovation Center, Inc.
14.3.20. Merck & Co., Inc.
14.3.21. Nordic BioSite
14.3.22. Novartis AG
14.3.23. Novo Nordisk A/S
14.3.24. Pfizer, Inc.
14.3.25. Sanofi S.A.
14.3.26. Takeda Pharmaceutical Company Limited
14.3.27. Thermo Fisher Scientific Inc.
15. ResearchAI
16. ResearchStatistics
17. ResearchContacts
18. ResearchArticles
19. Appendix
List of Figures
FIGURE 1. BIOPHARMACEUTICALS MARKET MULTI-CURRENCY
FIGURE 2. BIOPHARMACEUTICALS MARKET MULTI-LANGUAGE
FIGURE 3. BIOPHARMACEUTICALS MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY DRUG TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY DRUG TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024 VS 2030 (%)
FIGURE 10. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY DEVELOPMENT PHASE, 2024 VS 2030 (%)
FIGURE 12. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY DEVELOPMENT PHASE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. AMERICAS BIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 14. AMERICAS BIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. UNITED STATES BIOPHARMACEUTICALS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 16. UNITED STATES BIOPHARMACEUTICALS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. ASIA-PACIFIC BIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. ASIA-PACIFIC BIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. BIOPHARMACEUTICALS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 22. BIOPHARMACEUTICALS MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. BIOPHARMACEUTICALS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC PROTEINS, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY VACCINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY BIOSIMILARS, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY INSULIN BIOSIMILARS, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY MONOCLONAL ANTIBODIES BIOSIMILARS, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY BIOSIMILARS, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY SMALL MOLECULE DRUGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY BRANDED DRUGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY GENERIC DRUGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY SMALL MOLECULE DRUGS, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY CARDIOLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY CORONARY ARTERY DISEASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY HYPERTENSION, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY COVID-19, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY HIV/AIDS, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY INFLUENZA, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY DEVELOPMENT PHASE, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY CLINICAL TRIALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY PHASE I, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY PHASE II, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY PHASE III, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY PRECLINICAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY CONTINUOUS PRECLINICAL TRIALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY PRECLINICAL, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY REGULATORY APPROVAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 45. AMERICAS BIOPHARMACEUTICALS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 46. AMERICAS BIOPHARMACEUTICALS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 47. AMERICAS BIOPHARMACEUTICALS MARKET SIZE, BY BIOSIMILARS, 2018-2030 (USD MILLION)
TABLE 48. AMERICAS BIOPHARMACEUTICALS MARKET SIZE, BY SMALL MOLECULE DRUGS, 2018-2030 (USD MILLION)
TABLE 49. AMERICAS BIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 50. AMERICAS BIOPHARMACEUTICALS MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
TABLE 51. AMERICAS BIOPHARMACEUTICALS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 52. AMERICAS BIOPHARMACEUTICALS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 53. AMERICAS BIOPHARMACEUTICALS MARKET SIZE, BY DEVELOPMENT PHASE, 2018-2030 (USD MILLION)
TABLE 54. AMERICAS BIOPHARMACEUTICALS MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
TABLE 55. AMERICAS BIOPHARMACEUTICALS MARKET SIZE, BY PRECLINICAL, 2018-2030 (USD MILLION)
TABLE 56. AMERICAS BIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 57. ARGENTINA BIOPHARMACEUTICALS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 58. ARGENTINA BIOPHARMACEUTICALS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 59. ARGENTINA BIOPHARMACEUTICALS MARKET SIZE, BY BIOSIMILARS, 2018-2030 (USD MILLION)
TABLE 60. ARGENTINA BIOPHARMACEUTICALS MARKET SIZE, BY SMALL MOLECULE DRUGS, 2018-2030 (USD MILLION)
TABLE 61. ARGENTINA BIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 62. ARGENTINA BIOPHARMACEUTICALS MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
TABLE 63. ARGENTINA BIOPHARMACEUTICALS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 64. ARGENTINA BIOPHARMACEUTICALS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 65. ARGENTINA BIOPHARMACEUTICALS MARKET SIZE, BY DEVELOPMENT PHASE, 2018-2030 (USD MILLION)
TABLE 66. ARGENTINA BIOPHARMACEUTICALS MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
TABLE 67. ARGENTINA BIOPHARMACEUTICALS MARKET SIZE, BY PRECLINICAL, 2018-2030 (USD MILLION)
TABLE 68. BRAZIL BIOPHARMACEUTICALS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 69. BRAZIL BIOPHARMACEUTICALS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 70. BRAZIL BIOPHARMACEUTICALS MARKET SIZE, BY BIOSIMILARS, 2018-2030 (USD MILLION)
TABLE 71. BRAZIL BIOPHARMACEUTICALS MARKET SIZE, BY SMALL MOLECULE DRUGS, 2018-2030 (USD MILLION)
TABLE 72. BRAZIL BIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 73. BRAZIL BIOPHARMACEUTICALS MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
TABLE 74. BRAZIL BIOPHARMACEUTICALS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 75. BRAZIL BIOPHARMACEUTICALS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 76. BRAZIL BIOPHARMACEUTICALS MARKET SIZE, BY DEVELOPMENT PHASE, 2018-2030 (USD MILLION)
TABLE 77. BRAZIL BIOPHARMACEUTICALS MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
TABLE 78. BRAZIL BIOPHARMACEUTICALS MARKET SIZE, BY PRECLINICAL, 2018-2030 (USD MILLION)
TABLE 79. CANADA BIOPHARMACEUTICALS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 80. CANADA BIOPHARMACEUTICALS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 81. CANADA BIOPHARMACEUTICALS MARKET SIZE, BY BIOSIMILARS, 2018-2030 (USD MILLION)
TABLE 82. CANADA BIOPHARMACEUTICALS MARKET SIZE, BY SMALL MOLECULE DRUGS, 2018-2030 (USD MILLION)
TABLE 83. CANADA BIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 84. CANADA BIOPHARMACEUTICALS MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
TABLE 85. CANADA BIOPHARMACEUTICALS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 86. CANADA BIOPHARMACEUTICALS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 87. CANADA BIOPHARMACEUTICALS MARKET SIZE, BY DEVELOPMENT PHASE, 2018-2030 (USD MILLION)
TABLE 88. CANADA BIOPHARMACEUTICALS MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
TABLE 89. CANADA BIOPHARMACEUTICALS MARKET SIZE, BY PRECLINICAL, 2018-2030 (USD MILLION)
TABLE 90. MEXICO BIOPHARMACEUTICALS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 91. MEXICO BIOPHARMACEUTICALS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 92. MEXICO BIOPHARMACEUTICALS MARKET SIZE, BY BIOSIMILARS, 2018-2030 (USD MILLION)
TABLE 93. MEXICO BIOPHARMACEUTICALS MARKET SIZE, BY SMALL MOLECULE DRUGS, 2018-2030 (USD MILLION)
TABLE 94. MEXICO BIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 95. MEXICO BIOPHARMACEUTICALS MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
TABLE 96. MEXICO BIOPHARMACEUTICALS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 97. MEXICO BIOPHARMACEUTICALS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 98. MEXICO BIOPHARMACEUTICALS MARKET SIZE, BY DEVELOPMENT PHASE, 2018-2030 (USD MILLION)
TABLE 99. MEXICO BIOPHARMACEUTICALS MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
TABLE 100. MEXICO BIOPHARMACEUTICALS MARKET SIZE, BY PRECLINICAL, 2018-2030 (USD MILLION)
TABLE 101. UNITED STATES BIOPHARMACEUTICALS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 102. UNITED STATES BIOPHARMACEUTICALS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 103. UNITED STATES BIOPHARMACEUTICALS MARKET SIZE, BY BIOSIMILARS, 2018-2030 (USD MILLION)
TABLE 104. UNITED STATES BIOPHARMACEUTICALS MARKET SIZE, BY SMALL MOLECULE DRUGS, 2018-2030 (USD MILLION)
TABLE 105. UNITED STATES BIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 106. UNITED STATES BIOPHARMACEUTICALS MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
TABLE 107. UNITED STATES BIOPHARMACEUTICALS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 108. UNITED STATES BIOPHARMACEUTICALS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 109. UNITED STATES BIOPHARMACEUTICALS MARKET SIZE, BY DEVELOPMENT PHASE, 2018-2030 (USD MILLION)
TABLE 110. UNITED STATES BIOPHARMACEUTICALS MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
TABLE 111. UNITED STATES BIOPHARMACEUTICALS MARKET SIZE, BY PRECLINICAL, 2018-2030 (USD MILLION)
TABLE 112. UNITED STATES BIOPHARMACEUTICALS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 113. ASIA-PACIFIC BIOPHARMACEUTICALS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 114. ASIA-PACIFIC BIOPHARMACEUTICALS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 115. ASIA-PACIFIC BIOPHARMACEUTICALS MARKET SIZE, BY BIOSIMILARS, 2018-2030 (USD MILLION)
TABLE 116. ASIA-PACIFIC BIOPHARMACEUTICALS MARKET SIZE, BY SMALL MOLECULE DRUGS, 2018-2030 (USD MILLION)
TABLE 117. ASIA-PACIFIC BIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 118. ASIA-PACIFIC BIOPHARMACEUTICALS MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
TABLE 119. ASIA-PACIFIC BIOPHARMACEUTICALS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 120. ASIA-PACIFIC BIOPHARMACEUTICALS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 121. ASIA-PACIFIC BIOPHARMACEUTICALS MARKET SIZE, BY DEVELOPMENT PHASE, 2018-2030 (USD MILLION)
TABLE 122. ASIA-PACIFIC BIOPHARMACEUTICALS MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
TABLE 123. ASIA-PACIFIC BIOPHARMACEUTICALS MARKET SIZE, BY PRECLINICAL, 2018-2030 (USD MILLION)
TABLE 124. ASIA-PACIFIC BIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 125. AUSTRALIA BIOPHARMACEUTICALS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 126. AUSTRALIA BIOPHARMACEUTICALS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 127. AUSTRALIA BIOPHARMACEUTICALS MARKET SIZE, BY BIOSIMILARS, 2018-2030 (USD MILLION)
TABLE 128. AUSTRALIA BIOPHARMACEUTICALS MARKET SIZE, BY SMALL MOLECULE DRUGS, 2018-2030 (USD MILLION)
TABLE 129. AUSTRALIA BIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 130. AUSTRALIA BIOPHARMACEUTICALS MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
TABLE 131. AUSTRALIA BIOPHARMACEUTICALS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 132. AUSTRALIA BIOPHARMACEUTICALS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 133. AUSTRALIA BIOPHARMACEUTICALS MARKET SIZE, BY DEVELOPMENT PHASE, 2018-2030 (USD MILLION)
TABLE 134. AUSTRALIA BIOPHARMACEUTICALS MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
TABLE 135. AUSTRALIA BIOPHARMACEUTICALS MARKET SIZE, BY PRECLINICAL, 2018-2030 (USD MILLION)
TABLE 136. CHINA BIOPHARMACEUTICALS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 137. CHINA BIOPHARMACEUTICALS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 138. CHINA BIOPHARMACEUTICALS MARKET SIZE, BY BIOSIMILARS, 2018-2030 (USD MILLION)
TABLE 139. CHINA BIOPHARMACEUTICALS MARKET SIZE, BY SMALL MOLECULE DRUGS, 2018-2030 (USD MILLION)
TABLE 140. CHINA BIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 141. CHINA BIOPHARMACEUTICALS MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
TABLE 142. CHINA BIOPHARMACEUTICALS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 143. CHINA BIOPHARMACEUTICALS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 144. CHINA BIOPHARMACEUTICALS MARKET SIZE, BY DEVELOPMENT PHASE, 2018-2030 (USD MILLION)
TABLE 145. CHINA BIOPHARMACEUTICALS MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
TABLE 146. CHINA BIOPHARMACEUTICALS MARKET SIZE, BY PRECLINICAL, 2018-2030 (USD MILLION)
TABLE 147. INDIA BIOPHARMACEUTICALS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 148. INDIA BIOPHARMACEUTICALS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 149. INDIA BIOPHARMACEUTICALS MARKET SIZE, BY BIOSIMILARS, 2018-2030 (USD MILLION)
TABLE 150. INDIA BIOPHARMACEUTICALS MARKET SIZE, BY SMALL MOLECULE DRUGS, 2018-2030 (USD MILLION)
TABLE 151. INDIA BIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 152. INDIA BIOPHARMACEUTICALS MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
TABLE 153. INDIA BIOPHARMACEUTICALS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 154. INDIA BIOPHARMACEUTICALS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 155. INDIA BIOPHARMACEUTICALS MARKET SIZE, BY DEVELOPMENT PHASE, 2018-2030 (USD MILLION)
TABLE 156. INDIA BIOPHARMACEUTICALS MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
TABLE 157. INDIA BIOPHARMACEUTICALS MARKET SIZE, BY PRECLINICAL, 2018-2030 (USD MILLION)
TABLE 158. INDONESIA BIOPHARMACEUTICALS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 159. INDONESIA BIOPHARMACEUTICALS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 160. INDONESIA BIOPHARMACEUTICALS MARKET SIZE, BY BIOSIMILARS, 2018-2030 (USD MILLION)
TABLE 161. INDONESIA BIOPHARMACEUTICALS MARKET SIZE, BY SMALL MOLECULE DRUGS, 2018-2030 (USD MILLION)
TABLE 162. INDONESIA BIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 163. INDONESIA BIOPHARMACEUTICALS MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
TABLE 164. INDONESIA BIOPHARMACEUTICALS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 165. INDONESIA BIOPHARMACEUTICALS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 166. INDONESIA BIOPHARMACEUTICALS MARKET SIZE, BY DEVELOPMENT PHASE, 2018-2030 (USD MILLION)
TABLE 167. INDONESIA BIOPHARMACEUTICALS MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
TABLE 168. INDONESIA BIOPHARMACEUTICALS MARKET SIZE, BY PRECLINICAL, 2018-2030 (USD MILLION)
TABLE 169. JAPAN BIOPHARMACEUTICALS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 170. JAPAN BIOPHARMACEUTICALS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 171. JAPAN BIOPHARMACEUTICALS MARKET SIZE, BY BIOSIMILARS, 2018-2030 (USD MILLION)
TABLE 172. JAPAN BIOPHARMACEUTICALS MARKET SIZE, BY SMALL MOLECULE DRUGS, 2018-2030 (USD MILLION)
TABLE 173. JAPAN BIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 174. JAPAN BIOPHARMACEUTICALS MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
TABLE 175. JAPAN BIOPHARMACEUTICALS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 176. JAPAN BIOPHARMACEUTICALS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 177. JAPAN BIOPHARMACEUTICALS MARKET SIZE, BY DEVELOPMENT PHASE, 2018-2030 (USD MILLION)
TABLE 178. JAPAN BIOPHARMACEUTICALS MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
TABLE 179. JAPAN BIOPHARMACEUTICALS MARKET SIZE, BY PRECLINICAL, 2018-2030 (USD MILLION)
TABLE 180. MALAYSIA BIOPHARMACEUTICALS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 181. MALAYSIA BIOPHARMACEUTICALS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 182. MALAYSIA BIOPHARMACEUTICALS MARKET SIZE, BY BIOSIMILARS, 2018-2030 (USD MILLION)
TABLE 183. MALAYSIA BIOPHARMACEUTICALS MARKET SIZE, BY SMALL MOLECULE DRUGS, 2018-2030 (USD MILLION)
TABLE 184. MALAYSIA BIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 185. MALAYSIA BIOPHARMACEUTICALS MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
TABLE 186. MALAYSIA BIOPHARMACEUTICALS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 187. MALAYSIA BIOPHARMACEUTICALS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 188. MALAYSIA BIOPHARMACEUTICALS MARKET SIZE, BY DEVELOPMENT PHASE, 2018-2030 (USD MILLION)
TABLE 189. MALAYSIA BIOPHARMACEUTICALS MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
TABLE 190. MALAYSIA BIOPHARMACEUTICALS MARKET SIZE, BY PRECLINICAL, 2018-2030 (USD MILLION)
TABLE 191. PHILIPPINES BIOPHARMACEUTICALS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 192. PHILIPPINES BIOPHARMACEUTICALS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 193. PHILIPPINES BIOPHARMACEUTICALS MARKET SIZE, BY BIOSIMILARS, 2018-2030 (USD MILLION)
TABLE 194. PHILIPPINES BIOPHARMACEUTICALS MARKET SIZE, BY SMALL MOLECULE DRUGS, 2018-2030 (USD MILLION)
TABLE 195. PHILIPPINES BIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 196. PHILIPPINES BIOPHARMACEUTICALS MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
TABLE 197. PHILIPPINES BIOPHARMACEUTICALS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 198. PHILIPPINES BIOPHARMACEUTICALS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 199. PHILIPPINES BIOPHARMACEUTICALS MARKET SIZE, BY DEVELOPMENT PHASE, 2018-2030 (USD MILLION)
TABLE 200. PHILIPPINES BIOPHARMACEUTICALS MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
TABLE 201. PHILIPPINES BIOPHARMACEUTICALS MARKET SIZE, BY PRECLINICAL, 2018-2030 (USD MILLION)
TABLE 202. SINGAPORE BIOPHARMACEUTICALS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 203. SINGAPORE BIOPHARMACEUTICALS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 204. SINGAPORE BIOPHARMACEUTICALS MARKET SIZE, BY BIOSIMILARS, 2018-2030 (USD MILLION)
TABLE 205. SINGAPORE BIOPHARMACEUTICALS MARKET SIZE, BY SMALL MOLECULE DRUGS, 2018-2030 (USD MILLION)
TABLE 206. SINGAPORE BIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 207. SINGAPORE BIOPHARMACEUTICALS MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
TABLE 208. SINGAPORE BIOPHARMACEUTICALS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 209. SINGAPORE BIOPHARMACEUTICALS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 210. SINGAPORE BIOPHARMACEUTICALS MARKET SIZE, BY DEVELOPMENT PHASE, 2018-2030 (USD MILLION)
TABLE 211. SINGAPORE BIOPHARMACEUTICALS MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
TABLE 212. SINGAPORE BIOPHARMACEUTICALS MARKET SIZE, BY PRECLINICAL, 2018-2030 (USD MILLION)
TABLE 213. SOUTH KOREA BIOPHARMACEUTICALS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 214. SOUTH KOREA BIOPHARMACEUTICALS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 215. SOUTH KOREA BIOPHARMACEUTICALS MARKET SIZE, BY BIOSIMILARS, 2018-2030 (USD MILLION)
TABLE 216. SOUTH KOREA BIOPHARMACEUTICALS MARKET SIZE, BY SMALL MOLECULE DRUGS, 2018-2030 (USD MILLION)
TABLE 217. SOUTH KOREA BIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 218. SOUTH KOREA BIOPHARMACEUTICALS MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
TABLE 219. SOUTH KOREA BIOPHARMACEUTICALS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 220. SOUTH KOREA BIOPHARMACEUTICALS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 221. SOUTH KOREA BIOPHARMACEUTICALS MARKET SIZE, BY DEVELOPMENT PHASE, 2018-2030 (USD MILLION)
TABLE 222. SOUTH KOREA BIOPHARMACEUTICALS MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
TABLE 223. SOUTH KOREA BIOPHARMACEUTICALS MARKET SIZE, BY PRECLINICAL, 2018-2030 (USD MILLION)
TABLE 224. TAIWAN BIOPHARMACEUTICALS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 225. TAIWAN BIOPHARMACEUTICALS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 226. TAIWAN BIOPHARMACEUTICALS MARKET SIZE, BY BIOSIMILARS, 2018-2030 (USD MILLION)
TABLE 227. TAIWAN BIOPHARMACEUTICALS MARKET SIZE, BY SMALL MOLECULE DRUGS, 2018-2030 (USD MILLION)
TABLE 228. TAIWAN BIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 229. TAIWAN BIOPHARMACEUTICALS MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
TABLE 230. TAIWAN BIOPHARMACEUTICALS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 231. TAIWAN BIOPHARMACEUTICALS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 232. TAIWAN BIOPHARMACEUTICALS MARKET SIZE, BY DEVELOPMENT PHASE, 2018-2030 (USD MILLION)
TABLE 233. TAIWAN BIOPHARMACEUTICALS MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
TABLE 234. TAIWAN BIOPHARMACEUTICALS MARKET SIZE, BY PRECLINICAL, 2018-2030 (USD MILLION)
TABLE 235. THAILAND BIOPHARMACEUTICALS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 236. THAILAND BIOPHARMACEUTICALS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 237. THAILAND BIOPHARMACEUTICALS MARKET SIZE, BY BIOSIMILARS, 2018-2030 (USD MILLION)
TABLE 238. THAILAND BIOPHARMACEUTICALS MARKET SIZE, BY SMALL MOLECULE DRUGS, 2018-2030 (USD MILLION)
TABLE 239. THAILAND BIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 240. THAILAND BIOPHARMACEUTICALS MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
TABLE 241. THAILAND BIOPHARMACEUTICALS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 242. THAILAND BIOPHARMACEUTICALS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 243. THAILAND BIOPHARMACEUTICALS MARKET SIZE, BY DEVELOPMENT PHASE, 2018-2030 (USD MILLION)
TABLE 244. THAILAND BIOPHARMACEUTICALS MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
TABLE 245. THAILAND BIOPHARMACEUTICALS MARKET SIZE, BY PRECLINICAL, 2018-2030 (USD MILLION)
TABLE 246. VIETNAM BIOPHARMACEUTICALS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 247. VIETNAM BIOPHARMACEUTICALS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 248. VIETNAM BIOPHARMACEUTICALS MARKET SIZE, BY BIOSIMILARS, 2018-2030 (USD MILLION)
TABLE 249. VIETNAM BIOPHARMACEUTICALS MARKET SIZE, BY SMALL MOLECULE DRUGS, 2018-2030 (USD MILLION)
TABLE 250. VIETNAM BIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 251. VIETNAM BIOPHARMACEUTICALS MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
TABLE 252. VIETNAM BIOPHARMACEUTICALS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 253. VIETNAM BIOPHARMACEUTICALS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 254. VIETNAM BIOPHARMACEUTICALS MARKET SIZE, BY DEVELOPMENT PHASE, 2018-2030 (USD MILLION)
TABLE 255. VIETNAM BIOPHARMACEUTICALS MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
TABLE 256. VIETNAM BIOPHARMACEUTICALS MARKET SIZE, BY PRECLINICAL, 2018-2030 (USD MILLION)
TABLE 257. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICALS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 258. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICALS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 259. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICALS MARKET SIZE, BY BIOSIMILARS, 2018-2030 (USD MILLION)
TABLE 260. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICALS MARKET SIZE, BY SMALL MOLECULE DRUGS, 2018-2030 (USD MILLION)
TABLE 261. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 262. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICALS MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
TABLE 263. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICALS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 264. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICALS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 265. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICALS MARKET SIZE, BY DEVELOPMENT PHASE, 2018-2030 (USD MILLION)
TABLE 266. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICALS MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
TABLE 267. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICALS MARKET SIZE, BY PRECLINICAL, 2018-2030 (USD MILLION)
TABLE 268. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 269. DENMARK BIOPHARMACEUTICALS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 270. DENMARK BIOPHARMACEUTICALS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 271. DENMARK BIOPHARMACEUTICALS MARKET SIZE, BY BIOSIMILARS, 2018-2030 (USD MILLION)
TABLE 272. DENMARK BIOPHARMACEUTICALS MARKET SIZE, BY SMALL MOLECULE DRUGS, 2018-2030 (USD MILLION)
TABLE 273. DENMARK BIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 274. DENMARK BIOPHARMACEUTICALS MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
TABLE 275. DENMARK BIOPHARMACEUTICALS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 276. DENMARK BIOPHARMACEUTICALS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 277. DENMARK BIOPHARMACEUTICALS MARKET SIZE, BY DEVELOPMENT PHASE, 2018-2030 (USD MILLION)
TABLE 278. DENMARK BIOPHARMACEUTICALS MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
TABLE 279. DENMARK BIOPHARMACEUTICALS MARKET SIZE, BY PRECLINICAL, 2018-2030 (USD MILLION)
TABLE 280. EGYPT BIOPHARMACEUTICALS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 281. EGYPT BIOPHARMACEUTICALS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 282. EGYPT BIOPHARMACEUTICALS MARKET SIZE, BY BIOSIMILARS, 2018-2030 (USD MILLION)
TABLE 283. EGYPT BIOPHARMACEUTICALS MARKET SIZE, BY SMALL MOLECULE DRUGS, 2018-2030 (USD MILLION)
TABLE 284. EGYPT BIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 285. EGYPT BIOPHARMACEUTICALS MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
TABLE 286. EGYPT BIOPHARMACEUTICALS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 287. EGYPT BIOPHARMACEUTICALS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 288. EGYPT BIOPHARMACEUTICALS MARKET SIZE, BY DEVELOPMENT PHASE, 2018-2030 (USD MILLION)
TABLE 289. EGYPT BIOPHARMACEUTICALS MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
TABLE 290. EGYPT BIOPHARMACEUTICALS MARKET SIZE, BY PRECLINICAL, 2018-2030 (USD MILLION)
TABLE 291. FINLAND BIOPHARMACEUTICALS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 292. FINLAND BIOPHARMACEUTICALS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 293. FINLAND BIOPHARMACEUTICALS MARKET SIZE, BY BIOSIMILARS, 2018-2030 (USD MILLION)
TABLE 294. FINLAND BIOPHARMACEUTICALS MARKET SIZE, BY SMALL MOLECULE DRUGS, 2018-2030 (USD MILLION)
TABLE 295. FINLAND BIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 296. FINLAND BIOPHARMACEUTICALS MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
TABLE 297. FINLAND BIOPHARMACEUTICALS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 298. FINLAND BIOPHARMACEUTICALS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 299. FINLAND BIOPHARMACEUTICALS MARKET SIZE, BY DEVELOPMENT PHASE, 2018-2030 (USD MILLION)
TABLE 300. FINLAND BIOPHARMACEUTICALS MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
TABLE 301. FINLAND BIOPHARMACEUTICALS MARKET SIZE, BY PRECLINICAL, 2018-2030 (USD MILLION)
TABLE 302. FRANCE BIOPHARMACEUTICALS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 303. FRANCE BIOPHARMACEUTICALS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 304. FRANCE BIOPHARMACEUTICALS MARKET SIZE, BY BIOSIMILARS, 2018-2030 (USD MILLION)
TABLE 305. FRANCE BIOPHARMACEUTICALS MARKET SIZE, BY SMALL MOLECULE DRUGS, 2018-2030 (USD MILLION)
TABLE 306. FRANCE BIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 307. FRANCE BIOPHARMACEUTICALS MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
TABLE 308. FRANCE BIOPHARMACEUTICALS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 309. FRANCE BIOPHARMACEUTICALS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 310. FRANCE BIOPHARMACEUTICALS MARKET SIZE, BY DEVELOPMENT PHASE, 2018-2030 (USD MILLION)
TABLE 311. FRANCE BIOPHARMACEUTICALS MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
TABLE 312. FRANCE BIOPHARMACEUTICALS MARKET SIZE, BY PRECLINICAL, 2018-2030 (USD MILLION)
TABLE 313. GERMANY BIOPHARMACEUTICALS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 314. GERMANY BIOPHARMACEUTICALS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 315. GERMANY BIOPHARMACEUTICALS MARKET SIZE, BY BIOSIMILARS, 2018-2030 (USD MILLION)
TABLE 316. GERMANY BIOPHARMACEUTICALS MARKET SIZE, BY SMALL MOLECULE DRUGS, 2018-2030 (USD MILLION)
TABLE 317. GERMANY BIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 318. GERMANY BIOPHARMACEUTICALS MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
TABLE 319. GERMANY BIOPHARMACEUTICALS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 320. GERMANY BIOPHARMACEUTICALS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 321. GERMANY BIOPHARMACEUTICALS MARKET SIZE, BY DEVELOPMENT PHASE, 2018-2030 (USD MILLION)
TABLE 322. GERMANY BIOPHARMACEUTICALS MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
TABLE 323. GERMANY BIOPHARMACEUTICALS MARKET SIZE, BY PRECLINICAL, 2018-2030 (USD MILLION)
TABLE 324. ISRAEL BIOPHARMACEUTICALS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 325. ISRAEL BIOPHARMACEUTICALS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 326. ISRAEL BIOPHARMACEUTICALS MARKET SIZE, BY BIOSIMILARS, 2018-2030 (USD MILLION)
TABLE 327. ISRAEL BIOPHARMACEUTICALS MARKET SIZE, BY SMALL MOLECULE DRUGS, 2018-2030 (USD MILLION)
TABLE 328. ISRAEL BIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 329. ISRAEL BIOPHARMACEUTICALS MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
TABLE 330. ISRAEL BIOPHARMACEUTICALS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 331. ISRAEL BIOPHARMACEUTICALS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 332. ISRAEL BIOPHARMACEUTICALS MARKET SIZE, BY DEVELOPMENT PHASE, 2018-2030 (USD MILLION)
TABLE 333. ISRAEL BIOPHARMACEUTICALS MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
TABLE 334. ISRAEL BIOPHARMACEUTICALS MARKET SIZE, BY PRECLINICAL, 2018-2030 (USD MILLION)
TABLE 335. ITALY BIOPHARMACEUTICALS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 336. ITALY BIOPHARMACEUTICALS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 337. ITALY BIOPHARMACEUTICALS MARKET SIZE, BY BIOSIMILARS, 2018-2030 (USD MILLION)
TABLE 338. ITALY BIOPHARMACEUTICALS MARKET SIZE, BY SMALL MOLECULE DRUGS, 2018-2030 (USD MILLION)
TABLE 339. ITALY BIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 340. ITALY BIOPHARMACEUTICALS MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
TABLE 341. ITALY BIOPHARMACEUTICALS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 342. ITALY BIOPHARMACEUTICALS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 343. ITALY BIOPHARMACEUTICALS MARKET SIZE, BY DEVELOPMENT PHASE, 2018-2030 (USD MILLION)
TABLE 344. ITALY BIOPHARMACEUTICALS MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
TABLE 345. ITALY BIOPHARMAC

Companies Mentioned

  • Abbott Laboratories
  • AbbVie Inc.
  • Abgenex
  • Amgen Inc.
  • AstraZeneca PLC
  • Avidea Technologies
  • Bayer AG
  • Bio-Techne Corporation
  • Biogen Inc.
  • bioMérieux SA
  • Bristol-Myers Squibb Company
  • BTL Biotechno Labs Pvt. Ltd.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche AG
  • Ferring Pharmaceuticals
  • GlaxoSmithKline PLC
  • Ipsen Pharma
  • Johnson & Johnson Services, Inc.
  • LG Chem Life Sciences Innovation Center, Inc.
  • Merck & Co., Inc.
  • Nordic BioSite
  • Novartis AG
  • Novo Nordisk A/S
  • Pfizer, Inc.
  • Sanofi S.A.
  • Takeda Pharmaceutical Company Limited
  • Thermo Fisher Scientific Inc.

Methodology

Loading
LOADING...

Related Topics

Related Reports

Biopharmaceutical Market Outlook to 2029 - Product Image

Biopharmaceutical Market Outlook to 2029

  • Report
  • 97 Pages
  • Global
From
North America Biopharmaceuticals Market Forecast to 2028 -Regional Analysis - Product Image

North America Biopharmaceuticals Market Forecast to 2028 -Regional Analysis

  • Report
  • 224 Pages
  • North America
From
Asia Pacific Biopharmaceuticals Market Forecast to 2028 -Regional Analysis - Product Image

Asia Pacific Biopharmaceuticals Market Forecast to 2028 -Regional Analysis

  • Report
  • 250 Pages
  • Asia Pacific
From
Biopharmaceutical Fermentation - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2025 - 2030) - Product Image

Biopharmaceutical Fermentation - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2025 - 2030)

  • Report
  • 110 Pages
  • Global
From
Biopharmaceuticals Manufacturing Consumables Testing Market Size, Share & Trends Analysis Report By Service (Laboratory Testing, Custom Testing), By Raw Material (Formulation Excipients, API), By Region, And Segment Forecasts, 2025 - 2030 - Product Image

Biopharmaceuticals Manufacturing Consumables Testing Market Size, Share & Trends Analysis Report By Service (Laboratory Testing, Custom Testing), By Raw Material (Formulation Excipients, API), By Region, And Segment Forecasts, 2025 - 2030

  • Report
  • 100 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.